BioCentury
ARTICLE | Company News

Merck, CRT in deal for PRMT5 inhibitors

January 28, 2016 2:24 AM UTC

Merck & Co. Inc. (NYSE:MRK) partnered with Cancer Research Technology Ltd. to develop inhibitors of protein arginine methyltransferase 5, which the companies said have potential to treat cancer and non-cancer blood disorders.

The inhibitors were developed by Australian cooperative research center Cancer Therapeutics CRC Pty Ltd. (CTx) (Melbourne, Australia), with support from CRT and the Wellcome Trust. CRT is the commercialization and development arm of Cancer Research UK (London, U.K.). ...